<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7076512/results/search/disease/results.xml">
  <result pre="doi: 10.3390/pharmaceutics12020171pharmaceutics-12-00171 : Review Nanomaterials Designed for Antiviral Drug Delivery" exact="Transport" post="across Biological Barriers https://orcid.org/0000-0002-8076-6414CojocaruFlorina-Daniela1BotezatDoru1GardikiotisIoannis1https://orcid.org/0000-0002-7563-1267UrituCristina-Mariana1https://orcid.org/0000-0002-5551-6077DodiGianina1*TrandafirLaura2RezusCiprian3RezusElena4https://orcid.org/0000-0001-9868-1999TambaBogdan-Ionel1https://orcid.org/0000-0002-0945-5437MihaiCosmin-Teodor15[1], florina.cojocaru@umfiasi.rodoru.botezat@umfiasi.roioannis.gardikiotis@umfiasi.rocristina-mariana.uritu@umfiasi.robogdan.tamba@umfiasi.rocosmin-teodor.mihai@umfiasi.ro[2], laura.trandafir@umfiasi.ro[3], ciprian.rezus@umfiasi.ro[4], elena.rezus@umfiasi.ro[5], *Correspondence:"/>
  <result pre="of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract" exact="Viral" post="infections are a major global health problem, representing a"/>
  <result pre="the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Abstract Viral" exact="infections" post="are a major global health problem, representing a significant"/>
  <result pre="continuously amplified socio-economic impact. The increased drug resistance and constant" exact="viral" post="replication have been the trigger for important studies regarding"/>
  <result pre="have linked benefits for drug delivery as ideal tools for" exact="viral" post="treatment. Currently, different types of nanomaterials namely nanoparticles, liposomes,"/>
  <result pre="nanomedicines currently approved or undergoing investigations for the treatment of" exact="viral" post="infections are also discussed. Finally, the authors present an"/>
  <result pre="currently approved or undergoing investigations for the treatment of viral" exact="infections" post="are also discussed. Finally, the authors present an overview"/>
  <result pre="delivery biological barriers 1. Social Impact and Economic Burden of" exact="Viral" post="Infectious Diseases Today, we are living through a so-called"/>
  <result pre="biological barriers 1. Social Impact and Economic Burden of Viral" exact="Infectious" post="Diseases Today, we are living through a so-called fourth"/>
  <result pre="barriers 1. Social Impact and Economic Burden of Viral Infectious" exact="Diseases" post="Today, we are living through a so-called fourth great"/>
  <result pre="in McMichael’s description [1]). The current configuration and variety of" exact="infectious diseases" post="closely followed the combined evolutions in demography, environment, technology,"/>
  <result pre="to the induction of iatrogenic effects in some treatments for" exact="infections" post="such as hepatitis C, HIV and others [1]. In"/>
  <result pre="of iatrogenic effects in some treatments for infections such as" exact="hepatitis" post="C, HIV and others [1]. In recent decades, old"/>
  <result pre="at both the official and the general public levels regarding" exact="infectious diseases" post="as a threat to public health. McMichael [1] analyzed"/>
  <result pre="in social media and noticed the &quot;emergence and resurgence&quot; of" exact="infectious diseases" post="(determined by environmental, sociological and economic changes) and a"/>
  <result pre="is still a poor understanding of global economic impact of" exact="viral" post="diseases, which makes difficult to evaluate the societal costs"/>
  <result pre="preventive efforts. The issue of estimating a general impact of" exact="viral" post="infections involves several aspects that hinder this approach, namely:"/>
  <result pre="efforts. The issue of estimating a general impact of viral" exact="infections" post="involves several aspects that hinder this approach, namely: the"/>
  <result pre="several aspects that hinder this approach, namely: the variety of" exact="viral" post="infections, the incidence of associated co-morbidities, social and psychological"/>
  <result pre="and the presence of negative externalities [2], meaning that the" exact="disease" post="consequences are not limited to their patients infected or"/>
  <result pre="negative externalities [2], meaning that the disease consequences are not" exact="limited" post="to their patients infected or potentially but also to"/>
  <result pre="have become highways for microbial traffic; poverty perpetuates vulnerability to" exact="infectious disease;" post="and sexual practices, drug injecting, intensified food production and"/>
  <result pre="Rather, the impact can be split by relevant categories of" exact="viral" post="infections, were the literature is more precise but even"/>
  <result pre="Figure 1 presents statistical facts related to the most &quot;burden-generator&quot;" exact="viral infection" post="diseases [3,4,5,6,7]. HIV/AIDS, considered as one of the major"/>
  <result pre="1 presents statistical facts related to the most &quot;burden-generator&quot; viral" exact="infection" post="diseases [3,4,5,6,7]. HIV/AIDS, considered as one of the major"/>
  <result pre="[3,4,5,6,7]. HIV/AIDS, considered as one of the major burdens of" exact="disease" post="globally, became a chronic disease after the introduction of"/>
  <result pre="one of the major burdens of disease globally, became a" exact="chronic" post="disease after the introduction of multiple antiretroviral therapy (ART),"/>
  <result pre="of the major burdens of disease globally, became a chronic" exact="disease" post="after the introduction of multiple antiretroviral therapy (ART), and"/>
  <result pre="higher level of treatment costs for the HIV-affected households. Consequently," exact="HIV/AIDS" post="causes depletion of savings and productive assets, and increases"/>
  <result pre="the economic impact of HIV/AIDS. The household level impact of" exact="HIV/AIDS" post="includes direct costs, including medical and non-medical costs, and"/>
  <result pre="by others caring for them [10]. This evidence suggests that" exact="HIV/AIDS" post="places significant economic pressure on households trying to pay"/>
  <result pre="accurately quantifying and explaining the morbidity and mortality related to" exact="viral hepatitis" post="stems from the fact that hepatitis deaths are caused"/>
  <result pre="quantifying and explaining the morbidity and mortality related to viral" exact="hepatitis" post="stems from the fact that hepatitis deaths are caused"/>
  <result pre="mortality related to viral hepatitis stems from the fact that" exact="hepatitis" post="deaths are caused by five distinct viruses (hepatitis A–E)"/>
  <result pre="decades after infection, and that when people die with hepatitis-related" exact="liver cancer" post="and cirrhosis, these deaths are not always linked to"/>
  <result pre="after infection, and that when people die with hepatitis-related liver" exact="cancer" post="and cirrhosis, these deaths are not always linked to"/>
  <result pre="compared with other well-accepted medical interventions [12] due to sustained" exact="viral" post="response to therapy, the cost savings and quality-of-life improvement"/>
  <result pre="with respect to drug access in many countries. HSV and" exact="herpes zoster" post="(varicella-zosterian virus—VZV reactivation) are some of the most common"/>
  <result pre="respect to drug access in many countries. HSV and herpes" exact="zoster" post="(varicella-zosterian virus—VZV reactivation) are some of the most common"/>
  <result pre="zoster (varicella-zosterian virus—VZV reactivation) are some of the most common" exact="infections" post="in humans, with no effective treatment available at this"/>
  <result pre="forms, in most cases limiting methods are applied to local" exact="infection" post="and reducing side effects (pain, manifestations dermis etc.). Also,"/>
  <result pre="to the condition following diagnosis, in particular if they have" exact="acquired" post="the genital form of the disease. Feelings can include"/>
  <result pre="and intangible dimensions. It is widely accepted that estimating the" exact="total" post="social cost of a disease is useful in establishing"/>
  <result pre="widely accepted that estimating the total social cost of a" exact="disease" post="is useful in establishing policy decisions [14]. But there"/>
  <result pre="also other methods as the cross-sectional surveys of samples of" exact="primary" post="and secondary care physicians, analyzing health care resource utilization"/>
  <result pre="methods as the cross-sectional surveys of samples of primary and" exact="secondary" post="care physicians, analyzing health care resource utilization or approaches"/>
  <result pre="costs. These comprehensive studies can often be advantageous in allocating" exact="total" post="national expenditures among the major diagnostic categories [16]. However,"/>
  <result pre="and social aspects can vary substantially). But even in the" exact="absence of" post="global data of this nature, we still can extract"/>
  <result pre="of this paper: the current arrangements in the management of" exact="viral" post="infections (treatments, prevention and limitations of spread) are costly"/>
  <result pre="this paper: the current arrangements in the management of viral" exact="infections" post="(treatments, prevention and limitations of spread) are costly and"/>
  <result pre="to witness even further future growth. However, the list of" exact="viral" post="diseases for which antiviral therapies are available is still"/>
  <result pre="diseases for which antiviral therapies are available is still relatively" exact="short" post="[18]. There are several factors that hinder the development"/>
  <result pre="on host cell biosynthetic machinery [19], that leads to a" exact="limited" post="number of virus-specific metabolic functions can be targeted by"/>
  <result pre="for some viruses (as HSV and HIV) can treat the" exact="acute" post="illness, but do not cure the latent infection. This"/>
  <result pre="but do not cure the latent infection. This leads to" exact="recurrent" post="or chronic diseases that require treatment for longer periods"/>
  <result pre="do not cure the latent infection. This leads to recurrent" exact="or chronic" post="diseases that require treatment for longer periods of time"/>
  <result pre="not cure the latent infection. This leads to recurrent or" exact="chronic" post="diseases that require treatment for longer periods of time"/>
  <result pre="and the composition with DNA or RNA [20]. In humans," exact="viral" post="infections are responsible for different diseases as briefly presented"/>
  <result pre="the composition with DNA or RNA [20]. In humans, viral" exact="infections" post="are responsible for different diseases as briefly presented in"/>
  <result pre="nucleus and are dependent by host cell polymerases to replicate" exact="viral" post="genome. The virus may induce the cell to forcefully"/>
  <result pre="RNA (e.g., orthomyxoviruses, rhabdoviruses), that first must be transcribed by" exact="viral" post="polymerases (positive-sense) before can be directly accessed by host"/>
  <result pre="proteins. VI—ssRNA-RT viruses (+ strand or sense) RNA with DNA" exact="intermediate" post="in life-cycle (e.g., retroviruses), which use the reverse transcriptase"/>
  <result pre="into host genome by integrase. VII—dsDNA-RT viruses DNA with RNA" exact="intermediate" post="in life-cycle (e.g., hepadnaviruses), dsDNA viruses that replicate through"/>
  <result pre="a template and conversion to DNA is done by a" exact="viral" post="reverse transcriptase. There are distinct stages of viral replication"/>
  <result pre="by a viral reverse transcriptase. There are distinct stages of" exact="viral" post="replication (cell entry, uncoating, transcription of viral genome, translation"/>
  <result pre="distinct stages of viral replication (cell entry, uncoating, transcription of" exact="viral" post="genome, translation of viral proteins, post-translational modifications and assembly"/>
  <result pre="replication (cell entry, uncoating, transcription of viral genome, translation of" exact="viral" post="proteins, post-translational modifications and assembly of virion components) and"/>
  <result pre="acyclovir (ACV) and ganciclovir (GCV) were incorporated into nanomaterials; a" exact="complete" post="classification of HSV antivirals can be found in described"/>
  <result pre="as follows: the ACV selectivity is dependent by interaction with" exact="viral" post="HSV thymidine kinase and DNA polymerase, therefore the cellular"/>
  <result pre="monophospate to triphosphate ACV and this form of ACV inhibits" exact="viral" post="DNA polymerase and, to a much lesser extent, cellular"/>
  <result pre="extent, cellular DNA polymerase; ACV triphosphate is also integrated into" exact="viral" post="DNA and acts as a chain terminator, as it"/>
  <result pre="and acts as a chain terminator, as it binds to" exact="viral" post="DNA polymerase and determines its irreversible inactivation by a"/>
  <result pre="suicide inactivation [51,52,53]; occurrence of resistance to ACV could be" exact="acquired" post="by three mechanisms: impaired production of viral thymidine kinase"/>
  <result pre="ACV could be acquired by three mechanisms: impaired production of" exact="viral" post="thymidine kinase (the most common), altered thymidine kinase substrate"/>
  <result pre="specificity (e.g., phosphorylation of thymidine but not acyclovir), or altered" exact="viral" post="DNA polymerase (rare). Alterations in viral enzymes are caused"/>
  <result pre="not acyclovir), or altered viral DNA polymerase (rare). Alterations in" exact="viral" post="enzymes are caused by point mutations and base insertions"/>
  <result pre="in the corresponding genes [54]. The mechanism of GCV inhibits" exact="viral" post="DNA synthesis [55] as briefly explained below: it is"/>
  <result pre="[55] as briefly explained below: it is monophosphorylated intracellular by" exact="viral" post="thymidine kinase during HSV infection and by a viral"/>
  <result pre="it is monophosphorylated intracellular by viral thymidine kinase during HSV" exact="infection" post="and by a viral phosphotransferase encoded by the UL97"/>
  <result pre="by viral thymidine kinase during HSV infection and by a" exact="viral" post="phosphotransferase encoded by the UL97 gene during CMV infection,"/>
  <result pre="CMV can become resistant to GCV by mutations in the" exact="viral" post="phosphotransferase encoded by the UL97 gene and by mutations"/>
  <result pre="phosphotransferase encoded by the UL97 gene and by mutations in" exact="viral" post="DNA polymerase [56]. The conventional treatment (prophylaxis or therapy)"/>
  <result pre="[56]. The conventional treatment (prophylaxis or therapy) of an influenza" exact="virus infection," post="as a major public health concern worldwide, is designed"/>
  <result pre="a major public health concern worldwide, is designed to target" exact="viral" post="proteins and could be used, either alone or in"/>
  <result pre="to have broad-spectrum antiviral activity represent another possibility against influenza" exact="virus infection" post="[58,59,60]. Briefly, the antiviral mechanism of amantadine is based"/>
  <result pre="have broad-spectrum antiviral activity represent another possibility against influenza virus" exact="infection" post="[58,59,60]. Briefly, the antiviral mechanism of amantadine is based"/>
  <result pre="antiviral mechanism of amantadine is based on nterference with the" exact="viral" post="protein, M2 (an ion channel), the protein needed for"/>
  <result pre="protein, M2 (an ion channel), the protein needed for the" exact="viral" post="particle to become uncoated once it is taken inside"/>
  <result pre="are glycoproteins found on the virion surface, very important for" exact="viral" post="entry into uninfected cells, for the release of recently"/>
  <result pre="from infected cells, and for the further spread of the" exact="infectious" post="virus in the body [62,63]. Hepatitis viruses have been"/>
  <result pre="further spread of the infectious virus in the body [62,63]." exact="Hepatitis" post="viruses have been the subject of intense study in"/>
  <result pre="special attention on therapy. As mentioned in the first section," exact="hepatitis" post="treatment depends upon the type of hepatitis, therefore different"/>
  <result pre="two being produced by nearly all cells as response to" exact="viral" post="infections, while the third is restricted to T-lymphocytes and"/>
  <result pre="latent cellular endoribonuclease (RNase L) to cleave both cellular and" exact="viral" post="single-stranded RNAs. Antiretroviral therapy—ART—refers to the treatment with HIV"/>
  <result pre="reverse transcriptase into nascent DNA but lacks a 3′-hydroxyl group." exact="Resistance" post="to AZT is associated with mutations at reverse transcriptase"/>
  <result pre="Tenofovir disoproxil is a derivative of adenosine 5′-monophosphate lacking a" exact="complete" post="ribose ring, and it is the only nucleotide analogue"/>
  <result pre="the only nucleotide analogue currently marketed for the treatment of" exact="HIV infection," post="being active against HIV-1, HIV-2 and HBV. After a"/>
  <result pre="active metabolite, tenofovir diphosphate which is a competitive inhibitor of" exact="viral" post="reverse transcriptases and is incorporated into HIV DNA, causing"/>
  <result pre="preventing the metamorphosis of HIV virus particles into their mature" exact="infectious" post="form [77,78]. Only SQV, indinavir, ATV, RTV, NFV and"/>
  <result pre="as specified in Table 2. ENF inhibits fusion of the" exact="viral" post="and cell membranes mediated by gp41 and CD4 interactions,"/>
  <result pre="to the host cell CCR5 receptor to block binding of" exact="viral" post="gp120. As such, MCV is the only approved antiretroviral"/>
  <result pre="the organism. The &quot;security&quot; system includes physiological barriers, such as" exact="blood-brain barrier" post="(BBB), epithelium, stratum corneum, air-blood lung barrier [86], reproductive"/>
  <result pre="and BBB in antiviral therapy. 3.1. Mucus The gastrointestinal tract," exact="respiratory" post="system, the urogenital cavities, eyes and mouth, are all"/>
  <result pre="It is important to mention a &quot;special barrier&quot; namely the" exact="ocular" post="mucus that changes completely in 5 to 8 min,"/>
  <result pre="with mucolytic enzymes, pH dependent. Therefore, at acid pH, the" exact="absence of" post="disulphide bonds formation with cysteine-rich domains in mucins does"/>
  <result pre="fewer side effects with no need of regular treatment but" exact="systemic" post="distribution of the drug. Both methods of treatment have"/>
  <result pre="specified in Section 2, the current antiviral therapy for HSV" exact="infection" post="includes topical formulations of ACV that is unable permeate"/>
  <result pre="hair follicle. The stratum corneum is less intact in the" exact="lower" post="infundibulum, so the nanoparticle’s (NPs) passage is dependent on"/>
  <result pre="illness. The capillaries of BBB compose a layer of squamous" exact="epithelial" post="cells that fold to form a circular vessel. These"/>
  <result pre="strong connections for blocking entrance or exit of materials through" exact="central nervous system." post="Protein transportation facilitates the selective flow of molecules through"/>
  <result pre="blocking entrance or exit of materials through central nervous system." exact="Protein" post="transportation facilitates the selective flow of molecules through vessel"/>
  <result pre="and adjacent pericytes, astrocytes and neurons, but also neighbouring smooth" exact="muscle" post="cells and microglia in the brain, and blood cells"/>
  <result pre="capillary lumen such as polymorphonuclear cells, lymphocytes and monocytes [102]." exact="Transport" post="at the BBB level is assured by numerous transport"/>
  <result pre="cassette (ABC) efflux transporter family represented by permeability glycoprotein (P-gp)," exact="breast cancer" post="resistance protein (BCRP) and the multidrug resistance associated proteins"/>
  <result pre="(ABC) efflux transporter family represented by permeability glycoprotein (P-gp), breast" exact="cancer" post="resistance protein (BCRP) and the multidrug resistance associated proteins"/>
  <result pre="and therapeutic drugs, creating an important obstacle to treatment of" exact="brain cancer," post="epilepsy and neuro AIDS [107]. The penetration of the"/>
  <result pre="drugs, creating an important obstacle to treatment of brain cancer," exact="epilepsy" post="and neuro AIDS [107]. The penetration of the BBB"/>
  <result pre="likely routes include retrograde transport via the olfactory or trigeminal" exact="nerve" post="fibres, occasionally leading to herpes simplex encephalitis (HSE) caused"/>
  <result pre="via the olfactory or trigeminal nerve fibres, occasionally leading to" exact="herpes" post="simplex encephalitis (HSE) caused by HSV-1 [108]. Another studied"/>
  <result pre="olfactory or trigeminal nerve fibres, occasionally leading to herpes simplex" exact="encephalitis" post="(HSE) caused by HSV-1 [108]. Another studied virus that"/>
  <result pre="by HSV-1 [108]. Another studied virus that is involved in" exact="encephalitis" post="and BBB disruption is HIV, known to cause severe"/>
  <result pre="known to cause severe neurological disorders and leading to HIV-related" exact="encephalitis" post="[109] since BBB is impermeable to 98% of antiretroviral"/>
  <result pre="[110]. The possible mechanism responsible for BBB disruption in HIV-1" exact="encephalitis" post="is considered a &quot;Trojan horse&quot; mechanism, where HIV infects"/>
  <result pre="or by a monocyte-mediated transport, under the influence of an" exact="external" post="magnetic field [115]; novel nanodrug consisting of an iron"/>
  <result pre="is focused on manipulating these features that are relevant in" exact="viral" post="diseases where high drug doses are compulsory, implies high"/>
  <result pre="a review paper an interesting perspective of nanotechnology use in" exact="HIV/AIDS" post="vaccine development. Their overview underline the potential of various"/>
  <result pre="and also the gene delivery and immunotherapy nanocarriers used in" exact="cancer" post="with potential in HIV treatment. In Section 4. Nanocarriers"/>
  <result pre="overviewed nanotechnology-based systems as reliable alternative diagnostic tools for HCV" exact="infectious disease." post="Even if our review does not cover screening, it"/>
  <result pre="required in order to overcome current drawbacks of HCV under-diagnosed" exact="infection" post="as highlighted in the above-mentioned review. The nanotechnology-based tools"/>
  <result pre="ACV as a topical formulation against both HSV-1 and HSV-2" exact="herpes" post="virus strains. The main component, chitosan, a natural polycationic"/>
  <result pre="The IC50 value of HPAC corresponding to HSV-1 and HSV-2" exact="infection" post="in prophylactic administration was found of 0.8 and 1"/>
  <result pre="administration was found of 0.8 and 1 mg/mL, respectively, significantly" exact="lower" post="than clinically accepted TC50 value (half maximal toxicity concentration)"/>
  <result pre="efficacy on in vivo studies using a murine model of" exact="ocular" post="(HSV-1) and genital (HSV-2) infection were performed. As a"/>
  <result pre="using a murine model of ocular (HSV-1) and genital (HSV-2)" exact="infection" post="were performed. As a result, the ACV loaded HPAC"/>
  <result pre="not demonstrate a prophylactically antiviral response. 5.1.2. Nanomaterials with Antiviral" exact="Intrinsic" post="Activity Gold and Silver NPs Using Seaweed Sargassum wightii"/>
  <result pre="bonds is reported [169], so that by increasing the dilution" exact="viral" post="inhibition is lost, causing those compounds not to be"/>
  <result pre="on long and flexible linkers simulating HSPG, leading to irreversible" exact="viral" post="deformation. Of the synthesized compounds, the most notable virucidal"/>
  <result pre="MUS:OT-NPs exhibited efficient virucidal effect against HSV-1 and HSV-2, human" exact="papilloma" post="virus (HPV-16), respiratory syncytial virus (RSV), dengue and lenti"/>
  <result pre="virucidal effect against HSV-1 and HSV-2, human papilloma virus (HPV-16)," exact="respiratory" post="syncytial virus (RSV), dengue and lenti virus. The in"/>
  <result pre="RSV reveals the efficacy of MUS:OT-NPs treatment that prevented the" exact="pulmonary" post="dissemination of the infection. These results are in agreement"/>
  <result pre="values of ζ-potential may interact with negatively charged surface of" exact="mucosa" post="membrane, with beneficial consequences relating to transmucosal delivery of"/>
  <result pre="bioavailable drug, has serious side effects, the most common being" exact="bone marrow suppression," post="toxicity for some organs, neutropenia and anaemia. Specific target"/>
  <result pre="most common being bone marrow suppression, toxicity for some organs," exact="neutropenia" post="and anaemia. Specific target drug delivery using different nanosystems"/>
  <result pre="small NPs lactoferrin loaded with AZT (50–60 nm in size)," exact="stable" post="in biological simulated fluids (gastric and intestinal). Antiviral activity"/>
  <result pre="been included in films for drug delivery through the buccal" exact="mucosa" post="barrier. Four mucoadhesive polymers: polyvinyl alcohol—PVA, polyvinyl pyrrolidone—PVP, sodium"/>
  <result pre="PLGA NPs loaded with LAM and proved that are physicochemical" exact="stable" post="and slowly released the drug, a great property attributed"/>
  <result pre="are promising intestinal targeted drug delivery system for LMA, being" exact="stable" post="in tested media. In clinical practice, LAM is frequently"/>
  <result pre="delivery nanosystems for ATZ (52%) and LMA (58%). In vivo" exact="acute" post="toxicity has been studied in mice; the results proving"/>
  <result pre="of the drug in NPs showed a reduced toxicity to" exact="peripheral" post="blood mononuclear cells, Jurkat T cells and B16-F10 cells,"/>
  <result pre="studied as nanosystems for brain delivery using hCMEC/D3 as a" exact="blood-brain barrier" post="in vitro model, HCMEC/D3 being human brain microvessel endothelial"/>
  <result pre="can be used also for other grave medical disorders like" exact="cancer" post="[181]. Some studies have showed the ability of different"/>
  <result pre="loaded with NFV to activate latent HIV and to restrict" exact="viral" post="spread in vitro. Kovochich et al. [160] showed that"/>
  <result pre="and DRV in LNPs, but only ATV-LNPs proved to form" exact="stable" post="drug-lipid concentrations. Based on these results, the authors have"/>
  <result pre="has been tested on macrophages, human brain microendothelial cells and" exact="primary" post="peripheral blood mononuclear cells, the results suggesting that RAL—pMBA—Au-NPs"/>
  <result pre="been tested on macrophages, human brain microendothelial cells and primary" exact="peripheral" post="blood mononuclear cells, the results suggesting that RAL—pMBA—Au-NPs penetrate"/>
  <result pre="activity. In vivo studies performed by injection of RAL—pMBA—Au-NPs in" exact="female" post="adult BALB mice tail proved that the studied NPs"/>
  <result pre="In vivo studies performed by injection of RAL—pMBA—Au-NPs in female" exact="adult" post="BALB mice tail proved that the studied NPs could"/>
  <result pre="and (9) multifunctionality by combining several beneficial features in a" exact="stable" post="construct, designed to simultaneously stimulate the replication of latent"/>
  <result pre="possible via a synergistically approach. Since the development of &quot;best&quot;" exact="viral" post="carriers involves a multidisciplinary team, virologists should be directly"/>
  <result pre="which developed low-cost and &quot;cell-friendly&quot; nanogels that can efficiently prevent" exact="viral" post="infections, addressed these challenges [203]. Here, the flexible, nontoxic"/>
  <result pre="on dendritic polyglycerol sulfate mimic cellular surface receptors where several" exact="viral" post="families bind. The designed nanogels can multivalently interact with"/>
  <result pre="viral families bind. The designed nanogels can multivalently interact with" exact="viral" post="glycoproteins, shield virus surfaces, and efficiently block infection since"/>
  <result pre="interact with viral glycoproteins, shield virus surfaces, and efficiently block" exact="infection" post="since they act as robust inhibitors for these viruses."/>
  <result pre="patients. 8. Conclusions Treating or improving treatment success rate for" exact="viral" post="diseases are fundamental responsibilities. The established potential and boosted"/>
  <result pre="expectations for new therapeutic innovative strategies for attacking or eradicating" exact="viral" post="disorders. At present, studies explored numerous and diverse nano-platforms"/>
  <result pre="Interest The authors declare no conflict of interest. Abbreviations AIDS:" exact="acquired" post="immunodeficiency syndrome; ACV: acyclovir; Ag: silver; AM: amantadine; ART:"/>
  <result pre="The authors declare no conflict of interest. Abbreviations AIDS: acquired" exact="immunodeficiency" post="syndrome; ACV: acyclovir; Ag: silver; AM: amantadine; ART: antiretroviral"/>
  <result pre="GCV: gangiclovir; GMP: good manufacturing practice; AuNPs: gold nanoparticles; HBV:" exact="hepatitis" post="B virus; HCV: hepatitis C virus; HSV: herpes Simplex;"/>
  <result pre="manufacturing practice; AuNPs: gold nanoparticles; HBV: hepatitis B virus; HCV:" exact="hepatitis" post="C virus; HSV: herpes Simplex; HIV: human immunodeficiency virus;"/>
  <result pre="nanoparticles; HBV: hepatitis B virus; HCV: hepatitis C virus; HSV:" exact="herpes" post="Simplex; HIV: human immunodeficiency virus; HPAC: highly porous activated"/>
  <result pre="virus; HCV: hepatitis C virus; HSV: herpes Simplex; HIV: human" exact="immunodeficiency" post="virus; HPAC: highly porous activated carbon; HPMC: hydroxypropyl methylcellulose;"/>
  <result pre="TEM: transmission electron microscopy; Tf: transferrin; TFV: tenofovir; UNAIDS: The" exact="Joint" post="United Nations Programme on HIV/AIDS; VZV: varicella-zosterian virus; ζ-potential:"/>
  <result pre="zeta potential. References References 1.McMichaelA.J.Environmental and social influences on emerging" exact="infectious" post="diseases: Past, present and futurePhilos. Trans. R. Soc. Lond."/>
  <result pre="Nurse Application of the Ottawa Knee RuleAcad. Emerg. Med.2001811211610.1111/j.1553-2712.2001.tb01274.x11157285 3.The" exact="Joint" post="United Nations Programme on HIV/AIDSAvailable online: https://www.unaids.org/en(accessed on 27"/>
  <result pre="https://www.who.int/news-room/fact-sheets/detail/herpes-simplex-virus(accessed on 20 November 2019) 7.SzucsT.D.BergerK.FismanD.N.HarbarthS.The estimated economic burden of" exact="genital herpes" post="in the United States. An analysis using two costing"/>
  <result pre="on 20 November 2019) 7.SzucsT.D.BergerK.FismanD.N.HarbarthS.The estimated economic burden of genital" exact="herpes" post="in the United States. An analysis using two costing"/>
  <result pre="Res.201843 12.IyengarS.Tay-TeoK.VoglerS.BeyerP.WiktorS.de JoncheereK.HillS.Prices, Costs, and Affordability of New Medicines for" exact="Hepatitis" post="C in 30 Countries: An Economic AnalysisPLoS Med.201613e100203210.1371/journal.pmed.100203227243629 13.NoyesK.HollowayR.G.Evidence"/>
  <result pre="2019) 18.LemboD.CavalliR.Nanoparticulate Delivery Systems for Antiviral DrugsAntivir. Chem. Chemother.201021537010.3851/IMP168421107015 19.EisenreichW.RudelT.HeesemannJ.GoebelW.How" exact="Viral" post="and Intracellular Bacterial Pathogens Reprogram the Metabolism of Host"/>
  <result pre="Chem. Chemother.201021537010.3851/IMP168421107015 19.EisenreichW.RudelT.HeesemannJ.GoebelW.How Viral and Intracellular Bacterial Pathogens Reprogram the" exact="Metabolism" post="of Host Cells to Allow Their Intracellular ReplicationFront. Cell."/>
  <result pre="ReplicationFront. Cell. Infect. Microbiol.201994210.3389/fcimb.2019.0004230886834 20.Van RegenmortelM.H.V.Virus SpeciesGenetics and Evolution of" exact="Infectious" post="DisseaseElsevierAmsterdam, The Netherlands2011319 21.HeikkinenT.JärvinenA.The common coldLancet2003361515910.1016/S0140-6736(03)12162-912517470 22.FaithS.C.DurraniA.F.JhanjiV.Cytomegalovirus keratitisCurr. Opin."/>
  <result pre="The Netherlands2011319 21.HeikkinenT.JärvinenA.The common coldLancet2003361515910.1016/S0140-6736(03)12162-912517470 22.FaithS.C.DurraniA.F.JhanjiV.Cytomegalovirus keratitisCurr. Opin. Ophthalmol.20182937337710.1097/ICU.000000000000048129708927 23.KalezicT.MazenM.KuklinskiE.AsbellP.Herpetic" exact="eye disease" post="study: Lessons learnedCurr. Opin. Ophthalmol.20182934034610.1097/ICU.000000000000048229846207 24.JhanjiV.ChanT.C.Y.LiE.Y.M.AgarwalK.VajpayeeR.B.Adenoviral keratoconjunctivitisSurv. Ophthalmol.20156043544310.1016/j.survophthal.2015.04.00126077630 25.VenkatesanA.MurphyO.C.Viral"/>
  <result pre="Netherlands2011319 21.HeikkinenT.JärvinenA.The common coldLancet2003361515910.1016/S0140-6736(03)12162-912517470 22.FaithS.C.DurraniA.F.JhanjiV.Cytomegalovirus keratitisCurr. Opin. Ophthalmol.20182937337710.1097/ICU.000000000000048129708927 23.KalezicT.MazenM.KuklinskiE.AsbellP.Herpetic eye" exact="disease" post="study: Lessons learnedCurr. Opin. Ophthalmol.20182934034610.1097/ICU.000000000000048229846207 24.JhanjiV.ChanT.C.Y.LiE.Y.M.AgarwalK.VajpayeeR.B.Adenoviral keratoconjunctivitisSurv. Ophthalmol.20156043544310.1016/j.survophthal.2015.04.00126077630 25.VenkatesanA.MurphyO.C.Viral"/>
  <result pre="de Médecine Interne20173853153810.1016/j.revmed.2016.12.02228161113 28.RoseN.R.Viral myocarditisCurr. Opin. Rheumatol.20162838338910.1097/BOR.000000000000030327166925 29.Op de BeeckA.EizirikD.L.Viral" exact="infections" post="in type 1 diabetes mellitus—Why the β cells?Nat. Rev."/>
  <result pre="Interne20173853153810.1016/j.revmed.2016.12.02228161113 28.RoseN.R.Viral myocarditisCurr. Opin. Rheumatol.20162838338910.1097/BOR.000000000000030327166925 29.Op de BeeckA.EizirikD.L.Viral infections in" exact="type 1" post="diabetes mellitus—Why the β cells?Nat. Rev. Endocrinol.20161226327310.1038/nrendo.2016.3027020257 30.ThuenerJ.Hepatitis A"/>
  <result pre="myocarditisCurr. Opin. Rheumatol.20162838338910.1097/BOR.000000000000030327166925 29.Op de BeeckA.EizirikD.L.Viral infections in type 1" exact="diabetes" post="mellitus—Why the β cells?Nat. Rev. Endocrinol.20161226327310.1038/nrendo.2016.3027020257 30.ThuenerJ.Hepatitis A and"/>
  <result pre="cureWJG201622703010.3748/wjg.v22.i31.703027610014 34.KennedyP.GershonA.Clinical Features of Varicella-Zoster Virus InfectionViruses20181060910.3390/v10110609 35.ZerboniL.SenN.OliverS.L.ArvinA.M.Molecular mechanisms of" exact="varicella" post="zoster virus pathogenesisNat. Rev. Microbiol.20141219721010.1038/nrmicro321524509782 36.AgutH.BonnafousP.Gautheret-DejeanA.Human Herpesviruses 6A, 6B,"/>
  <result pre="34.KennedyP.GershonA.Clinical Features of Varicella-Zoster Virus InfectionViruses20181060910.3390/v10110609 35.ZerboniL.SenN.OliverS.L.ArvinA.M.Molecular mechanisms of varicella" exact="zoster" post="virus pathogenesisNat. Rev. Microbiol.20141219721010.1038/nrmicro321524509782 36.AgutH.BonnafousP.Gautheret-DejeanA.Human Herpesviruses 6A, 6B, and"/>
  <result pre="Clin. Off. Pract.20154251756710.1016/j.pop.2015.08.006 38.SchafferJ.V.BergerE.M.Molluscum ContagiosumJAMA Dermatol.2016152107210.1001/jamadermatol.2016.236727627044 39.KrenzerM.E.Viral Gastroenteritis in the" exact="Adult" post="PopulationCrit. Care Nurs. Clin. N. Am.20122454155310.1016/j.ccell.2012.07.003 40.EckardtA.J.BaumgartD.C.Viral Gastroenteritis in"/>
  <result pre="Nurs. Clin. N. Am.20122454155310.1016/j.ccell.2012.07.003 40.EckardtA.J.BaumgartD.C.Viral Gastroenteritis in AdultsPRI20116546310.2174/15748911179440787721210762 41.ThongprachumA.KhamrinP.ManeekarnN.HayakawaS.UshijimaH.Epidemiology of" exact="gastroenteritis" post="viruses in Japan: Prevalence, seasonality, and outbreak: Epidemiology of"/>
  <result pre="Gastroenteritis Viruses in JapanJ. Med. Virol.20168855157010.1002/jmv.2438726387663 42.ConeM.M.WhitlowC.B.Sexually Transmitted and Anorectal" exact="Infectious" post="DiseasesGastroenterol. Clin. N. Am.20134287789210.1016/j.gtc.2013.09.00324280405 43.Virus Taxonomy: 2018b ReleaseAvailable online:"/>
  <result pre="and lamivudine in HIV-1Antivir. Ther.20071233534317591023 50.LeungD.T.SacksS.L.Docosanol: A topical antiviral for" exact="herpes" post="labialisExp. Opin. Pharmacother.200452567257110.1517/14656566.5.12.2567 51.MillerW.H.MillerR.L.Phosphorylation of acyclovir diphosphate by cellular"/>
  <result pre="of acyclovirJ. Am. Acad. Dermatol.19881817617910.1016/S0190-9622(88)70022-52828440 53.O’BrienK.L.BaggettH.C.BrooksW.A.FeikinD.R.HammittL.L.HigdonM.M.HowieS.R.C.Deloria KnollM.KotloffK.L.LevineO.S.et al.Causes of severe" exact="pneumonia" post="requiring hospital admission in children without HIV infection from"/>
  <result pre="al.Causes of severe pneumonia requiring hospital admission in children without" exact="HIV infection" post="from Africa and Asia: The PERCH multi-country case-control studyLancet201939475777910.1016/S0140-6736(19)30721-431257127"/>
  <result pre="of severe pneumonia requiring hospital admission in children without HIV" exact="infection" post="from Africa and Asia: The PERCH multi-country case-control studyLancet201939475777910.1016/S0140-6736(19)30721-431257127"/>
  <result pre="An Update of its Use in the Prevention of Cytomegalovirus" exact="Infection" post="and Disease in Transplant RecipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 56.SchreiberA.HärterG.SchubertA.BunjesD.MertensT.MichelD.Antiviral treatment of cytomegalovirus"/>
  <result pre="of its Use in the Prevention of Cytomegalovirus Infection and" exact="Disease" post="in Transplant RecipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 56.SchreiberA.HärterG.SchubertA.BunjesD.MertensT.MichelD.Antiviral treatment of cytomegalovirus infection and"/>
  <result pre="Cytomegalovirus Infection and Disease in Transplant RecipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 56.SchreiberA.HärterG.SchubertA.BunjesD.MertensT.MichelD.Antiviral treatment of" exact="cytomegalovirus infection" post="and resistant strainsExp. Opin. Pharmacother.20091019120910.1517/1465656080267813819236193 57.De ClercqE.Antiviral agents active"/>
  <result pre="Infection and Disease in Transplant RecipientsDrugs2001611153118310.2165/00003495-200161080-0001611465876 56.SchreiberA.HärterG.SchubertA.BunjesD.MertensT.MichelD.Antiviral treatment of cytomegalovirus" exact="infection" post="and resistant strainsExp. Opin. Pharmacother.20091019120910.1517/1465656080267813819236193 57.De ClercqE.Antiviral agents active"/>
  <result pre="Biol.200921234134610.1242/jeb.02406719151208 60.YeganehB.GhavamiS.KroekerA.L.MahoodT.H.StelmackG.L.KlonischT.CoombsK.M.HalaykoA.J.Suppression of influenza A virus replication in human lung" exact="epithelial" post="cells by noncytotoxic concentrations bafilomycin A1Am. J. Physiol. Lung"/>
  <result pre="in adults and childrenCochrane Database Syst. Rev.201410.1002/14651858.CD008965.pub4 63.De JongM.D.ThanhT.T.KhanhT.H.HienV.M.SmithG.J.D.ChauN.V.CamB.V.QuiP.T.HaD.Q.GuanY.et al.Oseltamivir" exact="Resistance" post="during Treatment of Influenza A (H5N1) InfectionN. Engl. J."/>
  <result pre="Med.20053532667267210.1056/NEJMoa05451216371632 64.TeH.S.RandallG.JensenD.M.Mechanism of action of ribavirin in the treatment of" exact="chronic hepatitis" post="CGastroenterol. Hepatol.20073218225 65.KrečmerováM.Amino Acid Ester Prodrugs of Nucleoside and"/>
  <result pre="64.TeH.S.RandallG.JensenD.M.Mechanism of action of ribavirin in the treatment of chronic" exact="hepatitis" post="CGastroenterol. Hepatol.20073218225 65.KrečmerováM.Amino Acid Ester Prodrugs of Nucleoside and"/>
  <result pre="Microbiol. Rev.20031656959610.1128/CMR.16.4.569-596.200314557287 67.LeeH.W.ParkJ.Y.AhnS.H.An evaluation of entecavir for the treatment of" exact="chronic hepatitis" post="B infection in adultsExp. Rev. Gastroenterol. Hepatol.20161017718610.1586/17474124.2016.1125781 68.MatthewsS.Telbivudine for"/>
  <result pre="Rev.20031656959610.1128/CMR.16.4.569-596.200314557287 67.LeeH.W.ParkJ.Y.AhnS.H.An evaluation of entecavir for the treatment of chronic" exact="hepatitis" post="B infection in adultsExp. Rev. Gastroenterol. Hepatol.20161017718610.1586/17474124.2016.1125781 68.MatthewsS.Telbivudine for"/>
  <result pre="evaluation of entecavir for the treatment of chronic hepatitis B" exact="infection" post="in adultsExp. Rev. Gastroenterol. Hepatol.20161017718610.1586/17474124.2016.1125781 68.MatthewsS.Telbivudine for the management"/>
  <result pre="in adultsExp. Rev. Gastroenterol. Hepatol.20161017718610.1586/17474124.2016.1125781 68.MatthewsS.Telbivudine for the management of" exact="chronic hepatitis" post="B virus infectionClin. Ther.2007292635265310.1016/j.clinthera.2007.12.03218201580 69.AmarapurkarD.N.Telbivudine: A new treatment for"/>
  <result pre="adultsExp. Rev. Gastroenterol. Hepatol.20161017718610.1586/17474124.2016.1125781 68.MatthewsS.Telbivudine for the management of chronic" exact="hepatitis" post="B virus infectionClin. Ther.2007292635265310.1016/j.clinthera.2007.12.03218201580 69.AmarapurkarD.N.Telbivudine: A new treatment for"/>
  <result pre="hepatitis B virus infectionClin. Ther.2007292635265310.1016/j.clinthera.2007.12.03218201580 69.AmarapurkarD.N.Telbivudine: A new treatment for" exact="chronic hepatitis" post="BWJG200713615010.3748/wjg.v13.i46.615018069753 70.Antiretroviral Drugs Used in the Treatment of HIV"/>
  <result pre="B virus infectionClin. Ther.2007292635265310.1016/j.clinthera.2007.12.03218201580 69.AmarapurkarD.N.Telbivudine: A new treatment for chronic" exact="hepatitis" post="BWJG200713615010.3748/wjg.v13.i46.615018069753 70.Antiretroviral Drugs Used in the Treatment of HIV"/>
  <result pre="The first HIV integrase inhibitorClin. Ther.2008301747176510.1016/j.clinthera.2008.10.01219014832 84.HicksC.GulickR.M.Raltegravir: The First HIV" exact="Type 1" post="Integrase InhibitorClin. Infect. Dis.20094893193910.1086/59729019231980 85.Avila-OliasM.PegoraroC.BattagliaG.CantonI.Inspired by nature: Fundamentals in"/>
  <result pre="A Review of the State of the ArtIJMS201819154910.3390/ijms1906154929882846 90.collab: Herpetic" exact="Eye Disease" post="Study GroupOral acyclovir for herpes simplex virus eye disease:"/>
  <result pre="Review of the State of the ArtIJMS201819154910.3390/ijms1906154929882846 90.collab: Herpetic Eye" exact="Disease" post="Study GroupOral acyclovir for herpes simplex virus eye disease:"/>
  <result pre="the ArtIJMS201819154910.3390/ijms1906154929882846 90.collab: Herpetic Eye Disease Study GroupOral acyclovir for" exact="herpes" post="simplex virus eye disease: Effect on prevention of epithelial"/>
  <result pre="for herpes simplex virus eye disease: Effect on prevention of" exact="epithelial" post="keratitis and stromal keratitisArch. Ophthalmol.20001181030103610922194 91.DuraiR.Drug delivery approaches of"/>
  <result pre="herpes simplex virus eye disease: Effect on prevention of epithelial" exact="keratitis" post="and stromal keratitisArch. Ophthalmol.20001181030103610922194 91.DuraiR.Drug delivery approaches of an"/>
  <result pre="J. Med.199232778278910.1056/NEJM1992091032711081288525 93.YaldizM.SolakB.KaraR.O.CosansuN.ErdemM.T.Comparison of Famciclovir, Valaciclovir, and Brivudine Treatments in" exact="Adult" post="Immunocompetent Patients with Herpes ZosterAm. J. Ther.201825e626e63410.1097/MJT.000000000000043626808358 94.CugginoJ.C.BlancoE.R.O.GugliottaL.M.Alvarez IgarzabalC.I.CalderónM.Crossing"/>
  <result pre="Barrier: P-Glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize" exact="Central Nervous System" post="Drug DeliveryJ. Investig. Med.2012601131114010.2310/JIM.0b013e318276de79 103.EkC.J.WongA.LiddelowS.A.JohanssonP.A.DziegielewskaK.M.SaundersN.R.Efflux mechanisms at the developing"/>
  <result pre="P-Glycoprotein and Occludin Trafficking as Therapeutic Targets to Optimize Central" exact="Nervous System" post="Drug DeliveryJ. Investig. Med.2012601131114010.2310/JIM.0b013e318276de79 103.EkC.J.WongA.LiddelowS.A.JohanssonP.A.DziegielewskaK.M.SaundersN.R.Efflux mechanisms at the developing"/>
  <result pre="of the blood brain barrier is vital property of neurotropic" exact="viral infection" post="of the central nervous systemActa Virol.201862162710.4149/av_2018_10229521099 110.SagarV.Pilakka-KanthikeelS.PottathilR.SaxenaS.K.NairM.Towards nanomedicines for"/>
  <result pre="the blood brain barrier is vital property of neurotropic viral" exact="infection" post="of the central nervous systemActa Virol.201862162710.4149/av_2018_10229521099 110.SagarV.Pilakka-KanthikeelS.PottathilR.SaxenaS.K.NairM.Towards nanomedicines for"/>
  <result pre="for neuroAIDS: Nanomedicines for neuroAIDSRev. Med. Virol.20142410312410.1002/rmv.177824395761 111.LiuY.TangX.P.McArthurJ.C.ScottJ.GartnerS.Analysis of human" exact="immunodeficiency" post="virus type 1 gp160 sequences from a patient with"/>
  <result pre="Nanomedicines for neuroAIDSRev. Med. Virol.20142410312410.1002/rmv.177824395761 111.LiuY.TangX.P.McArthurJ.C.ScottJ.GartnerS.Analysis of human immunodeficiency virus" exact="type 1" post="gp160 sequences from a patient with HIV dementia: Evidence"/>
  <result pre="gp160 sequences from a patient with HIV dementia: Evidence for" exact="monocyte" post="trafficking into brainJ. Neurovirol.20006Suppl. 1S70S8110871768 112.KuoY.-C.ChenH.-H.Effect of nanoparticulate polybutylcyanoacrylate"/>
  <result pre="via transferrin anchored pegylated albumin nanoparticlesJ. Drug Target.200614455310.1080/1061186060061295316603451 114.JonesA.R.ShustaE.V.Blood–Brain Barrier" exact="Transport" post="of Therapeutics via Receptor-MediationPharm. Res.2007241759177110.1007/s11095-007-9379-017619996 115.SaiyedZ.GandhiN.NairM.Magnetic nanoformulation of azidothymidine"/>
  <result pre="for cancer, AIDS and brain disordersNanomedicine2009410511810.2217/17435889.4.1.10519093899 122.LiuY.ChenC.Role of nanotechnology in" exact="HIV/AIDS" post="vaccine developmentAdv. Drug Deliv. Rev.2016103768910.1016/j.addr.2016.02.01026952542 123.MilovanovicM.ArsenijevicA.MilovanovicJ.KanjevacT.ArsenijevicN.Nanoparticles in Antiviral TherapyAntimicrobial"/>
  <result pre="approaches to eradicating HIV reservoirsEur. J. Pharm. Biopharm.2019138486310.1016/j.ejpb.2018.06.00229879528 125.ShenY.TuJ.Preparation and" exact="ocular" post="pharmacokinetics of ganciclovir liposomesAAPS J.20079E37110.1208/aapsj090304418170984 126.FengM.CaiQ.ShiX.HuangH.ZhouP.GuoX.Recombinant high-density lipoprotein complex"/>
  <result pre="palmitate complexEur. J. Pharm. Biopharm.20086868869310.1016/j.ejpb.2007.07.00517890068 128.KimS.I.ShinD.LeeH.AhnB.-Y.YoonY.KimM.Targeted delivery of siRNA against" exact="hepatitis" post="C virus by apolipoprotein A-I-bound cationic liposomesJ. Hepatol.20095047948810.1016/j.jhep.2008.10.02919155084 129.KimS.-S.PeerD.KumarP.SubramanyaS.WuH.AsthanaD.HabiroK.YangY.-G.ManjunathN.ShimaokaM.et"/>
  <result pre="Hepatol.20095047948810.1016/j.jhep.2008.10.02919155084 129.KimS.-S.PeerD.KumarP.SubramanyaS.WuH.AsthanaD.HabiroK.YangY.-G.ManjunathN.ShimaokaM.et al.RNAi-mediated CCR5 Silencing by LFA-1-targeted Nanoparticles Prevents HIV" exact="Infection" post="in BLT MiceMol. Ther.20101837037610.1038/mt.2009.27119997090 130.PollockS.DwekR.A.BurtonD.R.ZitzmannN.N-Butyldeoxynojirimycin is a broadly effective"/>
  <result pre="by targeted liposome deliveryAIDS2008221961196910.1097/QAD.0b013e32830efd9618753929 131.GagnéJ.-F.DésormeauxA.PerronS.TremblayM.J.BergeronM.G.Targeted delivery of indinavir to HIV-1" exact="primary" post="reservoirs with immunoliposomesBBA Biomembr.2002155819821010.1016/S0005-2736(01)00432-1 132.ClaytonR.OhagenA.NicolF.Del VecchioA.M.JonckersT.H.M.GoethalsO.Van LoockM.MichielsL.GrigsbyJ.XuZ.et al.Sustained and"/>
  <result pre="with HDAC Plus Protease Inhibitors Activate Latent HIV and Inhibit" exact="Viral" post="SpreadNanoscale Res. Lett.20151041310.1186/s11671-015-1112-z26489856 145.VenkateshD.N.BaskaranM.KarriV.V.S.R.MannemalaS.S.RadhakrishnaK.GotiS.Fabrication and in vivo evaluation of"/>
  <result pre="Pharm. Biopharm.2019138303610.1016/j.ejpb.2018.05.01529777772 149.ShibataA.McMullenE.PhamA.BelshanM.SanfordB.ZhouY.GoedeM.DateA.A.DestacheC.J.Polymeric Nanoparticles Containing Combination Antiretroviral Drugs for HIV" exact="Type 1" post="TreatmentAIDS Res. Hum. Retrovir.20132974675410.1089/aid.2012.030123289671 150.PrathipatiP.K.MandalS.PonG.VivekanandanR.DestacheC.J.Pharmacokinetic and Tissue Distribution Profile"/>
  <result pre="al.Enhancing the Delivery of Anti Retroviral Drug &quot;Saquinavir&quot;; Across the" exact="Blood" post="Brain Barrier Using NanoparticlesCHR2010839640410.2174/15701621079133035620426757 155.DonalisioM.LeoneF.CivraA.SpagnoloR.OzerO.LemboD.CavalliR.Acyclovir-Loaded Chitosan Nanospheres from Nano-Emulsion"/>
  <result pre="the Delivery of Anti Retroviral Drug &quot;Saquinavir&quot;; Across the Blood" exact="Brain" post="Barrier Using NanoparticlesCHR2010839640410.2174/15701621079133035620426757 155.DonalisioM.LeoneF.CivraA.SpagnoloR.OzerO.LemboD.CavalliR.Acyclovir-Loaded Chitosan Nanospheres from Nano-Emulsion Templating"/>
  <result pre="situ and in vivo evaluationDrug Dev. Ind. Pharm.201440809110.3109/03639045.2012.74636223323843 157.AkhterS.TalegaonkarS.KhanZ.I.JainG.K.KharR.K.AhmadF.J.Assessment of" exact="Ocular" post="Pharmacokinetics and Safety of Ganciclovir Loaded NanoformulationsJ. Biomed. Nanotechnol.2011714414510.1166/jbn.2011.124121485843"/>
  <result pre="Delivery of the HIV Protease Inhibitor, Atazanavir, by a Human" exact="Brain" post="Endothelial Cell LinePharm. Res.2008252262227110.1007/s11095-008-9615-218516666 160.KovochichM.MarsdenM.D.ZackJ.A.Activation of Latent HIV Using"/>
  <result pre="as Triple-Drug Combination Levels in Cells Within Lymph Nodes and" exact="Blood" post="in PrimatesAIDS Res. Hum. Retrovir.20153110711410.1089/aid.2014.021025402233 163.Arca-LafuenteS.Martínez-RománP.Mate-CanoI.MadridR.BrizV.Nanotechnology: A reality for"/>
  <result pre="Res. Hum. Retrovir.20153110711410.1089/aid.2014.021025402233 163.Arca-LafuenteS.Martínez-RománP.Mate-CanoI.MadridR.BrizV.Nanotechnology: A reality for diagnosis of HCV" exact="infectious" post="diseaseJ. Infect.201910.1016/j.jinf.2019.09.010 164.FarzinL.ShamsipurM.SamandariL.SheibaniS.HIV biosensors for early diagnosis of infection:"/>
  <result pre="alga, Sargassum wightii GrevilleColloids Surf. B2007579710110.1016/j.colsurfb.2007.01.010 168.CagnoV.AndreozziP.D’AlicarnassoM.Jacob SilvaP.MuellerM.GallouxM.Le GofficR.JonesS.T.VallinoM.HodekJ.et al.Broad-spectrum" exact="non-toxic" post="antiviral nanoparticles with a virucidal inhibition mechanismNat. Mater.20181719520310.1038/nmat505329251725 169.KlimyteE.M.SmithS.E.OresteP.LemboD.DutchR.E.Inhibition"/>
  <result pre="Mater.20181719520310.1038/nmat505329251725 169.KlimyteE.M.SmithS.E.OresteP.LemboD.DutchR.E.Inhibition of Human Metapneumovirus Binding to Heparan Sulfate Blocks" exact="Infection" post="in Human Lung Cells and Airway TissuesJ. Virol.2016909237925010.1128/JVI.01362-1627489270 170.BhatiaS.CamachoL.C.HaagR.Pathogen"/>
  <result pre="HariB.N.Ramya DeviD.Design of antiretroviral drug-polymeric nanoparticles laden buccal films for" exact="chronic" post="HIV therapy in paediatricsColloid Interface Sci. Commun.201827495910.1016/j.colcom.2018.10.004 178.UrbaniakT.MusiałW.Influence of"/>
  <result pre="nanoparticlesEJPMR20144377383 181.SanchezC.G.MolinskiS.V.GongoraR.SosulskiM.FuselierT.MacKinnonS.S.MondalD.LaskyJ.A.The Antiretroviral Agent Nelfinavir Mesylate: A Potential Therapy for" exact="Systemic" post="SclerosisArthritis Rheumatol.20187011512610.1002/art.4032628940894 182.BowmanM.-C.BallardT.E.AckersonC.J.FeldheimD.L.MargolisD.M.MelanderC.Inhibition of HIV Fusion with Multivalent Gold"/>
  <result pre="Med. Chem.201571097110710.4155/fmc.15.5726132521 185.SinghL.KrugerH.G.MaguireG.E.M.GovenderT.ParboosingR.The role of nanotechnology in the treatment of" exact="viral" post="infectionsTher. Adv. Infect.2017410513110.1177/2049936117713593 186.BovierP.A.Epaxal®: A virosomal vaccine to prevent"/>
  <result pre="viral infectionsTher. Adv. Infect.2017410513110.1177/2049936117713593 186.BovierP.A.Epaxal®: A virosomal vaccine to prevent" exact="hepatitis" post="A infectionExp. Rev. Vaccines200871141115010.1586/14760584.7.8.1141 187.HeH.YuanD.WuY.CaoY.Pharmacokinetics and Pharmacodynamics Modeling and"/>
  <result pre="on 18 January 2020) 196.Study of ARB-001467 in Subjects with" exact="Chronic" post="HBV Infection Receiving Nucleos(t)Ide Analogue Therapy-ClinicalTrials.gov Identifier: NCT02631096Available online:"/>
  <result pre="January 2020) 196.Study of ARB-001467 in Subjects with Chronic HBV" exact="Infection" post="Receiving Nucleos(t)Ide Analogue Therapy-ClinicalTrials.gov Identifier: NCT02631096Available online: https://clinicaltrials.gov/ct2/show/NCT02631096?term=NCT02631096&amp;amp;draw=2&amp;amp;rank=1(accessed on"/>
  <result pre="by Blocking Virus EntryACS Nano2018126429644210.1021/acsnano.8b0161629894156 Figure 1 Global impact of" exact="viral" post="diseases. Figure 2 Summary of antiviral agents used in"/>
  <result pre="4 Nanocarriers developed for antiviral therapy. pharmaceutics-12-00171-t001_Table 1Table 1 Common" exact="viral" post="infections. Viral Infection Viruses References Common cold rhinoviruses, parainfluenza"/>
  <result pre="developed for antiviral therapy. pharmaceutics-12-00171-t001_Table 1Table 1 Common viral infections." exact="Viral Infection" post="Viruses References Common cold rhinoviruses, parainfluenza viruses, respiratory syncytial"/>
  <result pre="for antiviral therapy. pharmaceutics-12-00171-t001_Table 1Table 1 Common viral infections. Viral" exact="Infection" post="Viruses References Common cold rhinoviruses, parainfluenza viruses, respiratory syncytial"/>
  <result pre="infections. Viral Infection Viruses References Common cold rhinoviruses, parainfluenza viruses," exact="respiratory" post="syncytial viruses coronaviruses, Influenza viruses, adenoviruses, enteroviruses, metapneumovirus, unknown"/>
  <result pre="viruses coronaviruses, Influenza viruses, adenoviruses, enteroviruses, metapneumovirus, unknown [21] Eye" exact="infections" post="herpes simplex virus, adenovirus, cytomegalovirus [22,23,24] Encephalitis or meningitis"/>
  <result pre="coronaviruses, Influenza viruses, adenoviruses, enteroviruses, metapneumovirus, unknown [21] Eye infections" exact="herpes" post="simplex virus, adenovirus, cytomegalovirus [22,23,24] Encephalitis or meningitis as"/>
  <result pre="unknown [21] Eye infections herpes simplex virus, adenovirus, cytomegalovirus [22,23,24]" exact="Encephalitis" post="or meningitis as JC virus, measles, LCM virus, arbovirus,"/>
  <result pre="Eye infections herpes simplex virus, adenovirus, cytomegalovirus [22,23,24] Encephalitis or" exact="meningitis" post="as JC virus, measles, LCM virus, arbovirus, rabies [25]"/>
  <result pre="Encephalitis or meningitis as JC virus, measles, LCM virus, arbovirus," exact="rabies" post="[25] Pneumonia influenza virus (A and B), parainfluenza virus,"/>
  <result pre="meningitis as JC virus, measles, LCM virus, arbovirus, rabies [25]" exact="Pneumonia" post="influenza virus (A and B), parainfluenza virus, respiratory syncytial"/>
  <result pre="rabies [25] Pneumonia influenza virus (A and B), parainfluenza virus," exact="respiratory" post="syncytial virus, adenovirus, SARS coronavirus [26] Cardiovascular and pancreas"/>
  <result pre="virus, respiratory syncytial virus, adenovirus, SARS coronavirus [26] Cardiovascular and" exact="pancreas disease" post="coxsackie virus; [27,28,29] Hepatitis hepatitis viruses types A, B,"/>
  <result pre="respiratory syncytial virus, adenovirus, SARS coronavirus [26] Cardiovascular and pancreas" exact="disease" post="coxsackie virus; [27,28,29] Hepatitis hepatitis viruses types A, B,"/>
  <result pre="SARS coronavirus [26] Cardiovascular and pancreas disease coxsackie virus; [27,28,29]" exact="Hepatitis" post="hepatitis viruses types A, B, C, D, E [30,31,32,33]"/>
  <result pre="coronavirus [26] Cardiovascular and pancreas disease coxsackie virus; [27,28,29] Hepatitis" exact="hepatitis" post="viruses types A, B, C, D, E [30,31,32,33] Skin"/>
  <result pre="hepatitis viruses types A, B, C, D, E [30,31,32,33] Skin" exact="infections" post="varicella-zoster virus, human herpesvirus 6, smallpox, molluscum contagiosum, human"/>
  <result pre="E [30,31,32,33] Skin infections varicella-zoster virus, human herpesvirus 6, smallpox," exact="molluscum contagiosum," post="human papillomavirus, parvovirus B19, rubella, measles, coxsackie A virus"/>
  <result pre="Gastroenteritis adenoviruses, rotaviruses, noroviruses, astroviruses, coronaviruses [39,40,41] Sexually transmitted diseases" exact="herpes" post="simplex type 2, human papillomavirus HIV [42] pharmaceutics-12-00171-t002_Table 2Table"/>
  <result pre="rotaviruses, noroviruses, astroviruses, coronaviruses [39,40,41] Sexually transmitted diseases herpes simplex" exact="type 2," post="human papillomavirus HIV [42] pharmaceutics-12-00171-t002_Table 2Table 2 Nano-delivery systems"/>
  <result pre="around 10 times smaller than ACV-lipososmes; ACV [127] - cationic" exact="Viral" post="gene expression reduce by 65–75% in liver after 2"/>
  <result pre="days of administration at mice; siRNA HCV [128] - immunoliposomes" exact="Viral" post="secretion reduced by 81% and free viral particles neutralized"/>
  <result pre="[128] - immunoliposomes Viral secretion reduced by 81% and free" exact="viral" post="particles neutralized in vitro; HIV gp 120 Folding inhibitor"/>
  <result pre="gp 120 Folding inhibitor HIV [129,130,131] In vivo resistance to" exact="infection" post="has been enhanced; anti-CCR5 siRNA Immunoliposomes diameter with average"/>
  <result pre="PIs [132] Nanoparticles - HPAC HPAC (different concentrations)—non-cytotoxic for human" exact="epithelial" post="cells (corneal, vaginal), HeLa cells, foreskin fibroblasts: cell viability"/>
  <result pre="nm, compared with SeNPs size which is 200 nm; Se@AM—more" exact="stable" post="than SeNPs; Se@AM—superior antivirial effect on kidney cells treated"/>
  <result pre="and uniformly spherical particles; Ag@AM size of 2 nm; highly" exact="stable" post="NPs for more than 28 days; NPs loaded with"/>
  <result pre="of 103 nm, ζ-potential around −23 mV; polydisperse NPs; Chemically" exact="stable" post="NPs proved by FTIR and DSC; EFV [146] -"/>
  <result pre="cell viability: between 88% and 98% (neuro cells, Hela cells," exact="glioma" post="cells); AZT HIV [118] Nanorods - PVP-PEG coated with"/>
  <result pre="23–200 nm spherical particles; Nontoxic and noniritant nanoplatforms (New Zealand" exact="albino" post="rabbit); GCV HSV [157] SLNs - Borneol Microemulsion-based method;"/>
 </snippets>
</snippetsTree>
